Eli Lilly at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Eli Lilly brings 22 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 509, 900, Suite 4, Suite 11, Suite 12, Suite 19, Suite 19a, Suite 19b, Suite 19c, Suite 19d, Suite 19e, Suite 27. Its program centers on tirzepatide, from SURMOUNT trial analyses to real-world weight loss, healthcare costs and quality of life in women. It also covers newer agents, including how eloralintide affects food noise, cravings and alcohol use, and patient views on starting orforglipron.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, IN | ◆Platinum Sponsor |
Global medicine company working in diabetes, obesity and its long-term complications, Alzheimer's disease, immune disorders and hard-to-treat cancers. | Booth Exhibiting at Booth 509, 900, Suite 4, Suite 11, Suite 12, Suite 19, Suite 19a, Suite 19b, Suite 19c, Suite 19d, Suite 19e, Suite 27 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sat Nov 14 12:00pm–1:00pm Women Inspiring and Elevating Leadership in Diabetes (WIELD): Pearls of Wisdom from Obesity Trailblazers Across Career Stages and Fields Women leaders from academia and industry share career-building strategies for trainees and established investigators, with time to network. Poster Sat Nov 14 7:30pm–8:30pm Eloralintide Added to Established Tirzepatide Enhanced Weight and Fat Loss in DIO Rats Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Significant Increases in SHBG Accompanying Weight Loss with Tirzepatide in the SURMOUNT Program Chronic disease and obesity complicationsMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Two-year HbA1c and Weight Outcomes by Tirzepatide Persistence Pattern in Type 2 Diabetes Metabolism and integrative physiology Talk Sun Nov 15 7:30am–8:30am Weight Management Foundayo Peer-led review of dosing, efficacy and safety for a once-daily oral obesity medicine for adults, with time for audience questions. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and food Poster Sun Nov 15 2:30pm–3:30pm Weight-Loss Targets for Predicting Glucose Normalization: SURMOUNT-1 176-Week Post-Hoc Analysis Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Patients Reported Orforglipron Was Simple, Convenient, Easy to Use: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Reasons for Orforglipron Initiation and Treatment Goals: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Phase 2 Study of Tirzepatide Plus Mibavademab Compared with Tirzepatide Alone in Adults With Obesity Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Loss with 18-Month Tirzepatide Use in Adults with Obesity and without Diabetes Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Healthcare Costs Trends with Tirzepatide Use in Treatment of Obesity: A Matched Cohort Analysis Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes Among Zepbound (Tirzepatide) Users Engaging with the Lilly Health App Obesity pharmacotherapy and drug developmentInterventional and clinical studies Talk Sun Nov 15 3:30pm–3:45pm Talk Sun Nov 15 6:30pm–8:00pm One Patient, Many Perspectives: A Multidisciplinary Expert Roundtable on Obesity Care Specialists from primary care, cardiology, sleep medicine, surgery and other fields discuss one shared patient case to show how coordinated obesity care works. Metabolism and integrative physiologyInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceChronic disease and obesity complications Talk Mon Nov 16 7:00am–8:30am Beyond the Airway: Metabolic Drivers of Obstructive Sleep Apnea Small-group work through patient cases on how excess body fat contributes to obstructive sleep apnea, and on screening, diagnosis and treatment choices. Chronic disease and obesity complications Talk Mon Nov 16 7:15am–8:15am Seen Beyond the Scale: Addressing Weight Bias and Stigma in Pediatric Obesity Care Looks at how weight bias and stigma show up in pediatric care and gives clinicians ways to talk about weight respectfully with families. Pediatric and adolescent obesityClinical obesity care and professional practicePolicy and public health Talk Mon Nov 16 8:45am–9:00am Talk Mon Nov 16 11:45am–1:15pm Discover Zepbound (Tirzepatide) Injection Reviews efficacy, safety and dosing evidence for tirzepatide injection and how to identify adult patients who may be suitable for it. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 1:30pm–1:45pm Focus on Transitioning from Academia to Industry as Early Career Researcher Metabolism and integrative physiologyNeuroscience of appetite and eatingInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Achieving Clinical Goals with Tirzepatide Treatment in the SURMOUNT-MAINTAIN Trial: A Post-hoc Analysis Pediatric and adolescent obesityObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm Poster Mon Nov 16 2:30pm–3:30pm |
Find decision makers at Eli Lilly
Tell us what you sell and we’ll find the people at Eli Lilly most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction